obesity research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-14 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
== Function == PPARG regulates fatty acid storage and glucose metabolism. The genes activated by PPARG stimulate lipid uptake and adipogenesis by fat cells. PPARG knockout mice are devoid of adipose tissue, establishing PPARG as a master regulator of adipocyte differentiation. PPARG increases insulin sensitivity by enhancing storage of fatty acids in fat cells (reducing lipotoxicity), by enhancing adiponectin release from fat cells, by inducing FGF21, and by enhancing nicotinic acid adenine dinucleotide phosphate production through upregulation of the CD38 enzyme in mice. PPARG promotes anti-inflammatory M2 macrophage activation in mice. Adiponectin induces ABCA1-mediated reverse cholesterol transport by activation of PPAR-γ and LXRα/β. Many naturally occurring agents directly bind with and activate PPAR gamma. These agents include various polyunsaturated fatty acids like arachidonic acid and arachidonic acid metabolites such as certain members of the 5-hydroxyicosatetraenoic acid and 5-oxo-eicosatetraenoic acid family, e.g., 5-oxo-15(S)-HETE and 5-oxo-ETE or 15-hydroxyicosatetraenoic acid family including 15(S)-HETE, 15(R)-HETE, and 15(S)-HpETE, the phytocannabinoid tetrahydrocannabinol (THC), its metabolite THC-COOH, and its synthetic analog ajulemic acid (AJA). The activation of PPAR gamma by these and other ligands may be responsible for inhibiting the growth of cultured human breast, gastric, lung, prostate and other cancer cell lines. During embryogenesis, PPARG first substantially expresses in the interscapular brown fat pad in mice.
About 75% can be found in the dorsal area. Most of the congenital type-III cysts can be found posteriorly to the spinal cord, as opposed to those caused by trauma which can be found anteriorly to the spinal cord.Post traumatic inflammation induces cavitation and cystic formation and leads to greater secondary CNS injury. Cellular migration causing these cyst cavities was observed both in vitro and in vivo and cavitation was observed to be prevented with the use of an anti-inflammatory. Further more migration inflammatory cells into traumatized tissue has been observed with inflammation.
Direct-acting antagonist- which takes up space present on receptors which are otherwise taken up by neurotransmitters themselves. This results in neurotransmitters being blocked from binding to the receptors. An example of one of the most common is called Atropine. Indirect-acting antagonist- drugs that inhibit the release/production of neurotransmitters (e.g., reserpine).
The city has a rich sporting heritage as the home to two historically significant football teams: Juventus FC (founded in 1897) and Torino FC (founded in 1906). Juventus has the larger fan base, especially all over Italy and worldwide, while Torino enjoys a greater support in the city itself. The two clubs contest the oldest derby in Italy, the Derby della Mole. Juventus is Italy's most successful football club and one of the most successful in the world. It ranks joint twelfth in the list of the world's clubs with the most official international titles (sixth between European clubs), and was the first in association football history—remaining the only one in the world (as of 2022, after the first UEFA Europa Conference League Final)—to have won all possible official continental competitions and the world title. Juventus' owned ground, the Juventus Stadium, was inaugurated in 2011 and hosted the 2014 UEFA Europa League final, the 2021 Nations League finals and the 2022 Women's Champions League final. This was the first time the city hosted a seasonal UEFA club competition's single-match final. Juventus' female team has won, among others, five straight Serie A titles since its inception in 2017, becoming one of the most winning teams in the country. Torino FC was founded by the union of one of the oldest football teams in Turin, Football Club Torinese (founded in 1894), with breakaways from Juventus and was the most successful team, called "Grande Torino", in the Serie A during the 1940s.
=== Glucose transporter (GLUTs) === The glucose transporter (GLUTs) is a type of uniporter responsible for the facilitated diffusion of glucose molecules across cell membranes.Glucose is a vital energy source for most living cells, however, due to its large size, it cannot freely move through the cell membrane. The glucose transporter is specialized in transporting glucose specifically across the membrane. The GLUT proteins have several types of isoforms, each distributed in different tissues and exhibiting different kinetic properties.
Sources: en.wikipedia.org
=== Tunable resistive pulse sensing instruments === The Exoid is the most recent tunable resistive pulse sensing instrument developed by Izon Science and incorporates automated systems to avoid the extensive manual tuning associated with the qNano. Previously, with the qNano, there were many manual components: nanopore stretch had to be adjusted manually using a handle, and pressure was adjusted manually via a variable pressure module (VPM). In contrast, the Exoid automatically adjusts stretch, voltage and pressure, after parameters are selected using the software. The Exoid is capable of measuring the size, concentration, and zeta potential of individual particles sized between approximately 40 nm and 10 μm. The qNano is the original TRPS instrument by Izon Science, and remained the main TRPS instrument from its release in June 2009 until it was replaced by the Exoid in March 2021. Unlike the qNano, the Exoid has built-in semi-automated components for controlling pressure and nanopore stretch, and an enhanced voltage clamp amplifier. The qNano required manual tuning to adjust the stretch of the nanopore and the electrokinetic pressure, while voltage was selected via the software program. Nanopore stretch was adjusted using a handle, while pressure was adjusted by using a variable pressure module to manage a tube and plunger system. There were several updates to the qNano following its release including the addition of a pressure readout module.
== Post-playing career == Following his retirement, Ryder announced his return to Essendon Football Club for the first time since his departure following the 2014 season. Ryder will be the club's Indigenous Player Development Manager. Some of the players Ryder will work with include 2 sons of former teammate Alwyn Davey. Ryder had previously left the club following the supplements saga.
Blockage of voltage-dependent sodium channels (after activation of the channel, diclofenac inhibits its reactivation, also known as phase inhibition) Blockage of acid-sensing ion channels (ASICs) Positive allosteric modulation of KCNQ- and BK-potassium channels (diclofenac opens these channels, leading to hyperpolarization of the cell membrane) The duration of action (i.e., duration of pain relief) of a single dose is longer (6 to 8 h) than the drug's 1.2–2 h half-life. This may be partly due to its persistence for over 11 hours in synovial fluids.
=== Health === DHIS2 is currently in use as a Health Management Information System in more than 75 low- and middle-income countries. 69 of these countries have deployed DHIS2 at national scale. DHIS2 is also used by national health authorities and international health programs and organizations for management of health programs related to specific diseases, such as HIV, TB, and Malaria, among others, as well as for general public health programs such as disease surveillance, routine immunization, and maternal and child health. In 2025, Bangladesh implemented an electronic health information system using the DHIS2 Tracker to manage and evaluate its national cervical screening program. In addition, during the COVID-19 pandemic, 55 countries rapidly deployed or extended DHIS2 for national pandemic response and/or vaccination.
== Measurement == Formulas have been devised to estimate energy expenditure in humans, but they may not be accurate. Specifically they may not account for the effect of certain illnesses or the elderly. Not all formula are accurate in overweight or obese individuals. Traditional models for measuring human energy expenditure assumes that one's total daily energy expenditure (TDEE) is the simple additive sum of the measurement of each part of the body (e.g., resting metabolic rate, skeletal movement, and non-movement energy expenditures such as reproduction, digestion, immune system, etc.). Yet recent evidence suggests that the additive model may be accurate only up to an initial daily energy tipping point, after which the sum of the activities do not result in more energy expenditure, thus reflecting a constrained metabolic system. This is called the constrained daily energy expenditure model. Wearable devices can help estimate energy expenditure from physical activity but their accuracy varies.
Sources: en.wikipedia.org
During cell division, a single cell, the mother cell divides into two daughter cells. This leads to the growth of tissue in multicellular organisms. Prokaryotic cells divide by binary fission, while eukaryotic cells usually undergo a process of nuclear division, called mitosis, followed by division of the cell, called cytokinesis. A diploid cell may undergo meiosis to produce haploid cells, usually four. Haploid cells serve as gametes in multicellular organisms, fusing to form new diploid cells. DNA replication, or the process of duplicating a cell's genome, always happens when a cell divides through mitosis or binary fission. This occurs during the S (synthesis) phase of the cell cycle. In meiosis, the DNA is replicated only once, while the cell divides twice. DNA replication only occurs before meiosis I. DNA replication does not occur when the cells divide the second time, in meiosis II. Replication, like all cellular activities, requires specialized proteins.
Poly(A) polymerase then adds about 200 adenine units to the new 3' end of the RNA molecule using ATP as a precursor. As the poly(A) tail is synthesized, it binds multiple copies of poly(A)-binding protein, which protects the 3'end from ribonuclease digestion by enzymes including the CCR4-Not complex.
The first medicinal use of GM bacteria was to produce the protein insulin to treat diabetes. Other medicines produced include clotting factors to treat hemophilia, human growth hormone to treat various forms of dwarfism, interferon to treat some cancers, erythropoietin for anemic patients, and tissue plasminogen activator which dissolves blood clots. Outside of medicine they have been used to produce biofuels. There is interest in developing an extracellular expression system within the bacteria to reduce costs and make the production of more products economical. With a greater understanding of the role that the microbiome plays in human health, there is a potential to treat diseases by genetically altering the bacteria to, themselves, be therapeutic agents. Ideas include altering gut bacteria so they destroy harmful bacteria, or using bacteria to replace or increase deficient enzymes or proteins. One research focus is to modify Lactobacillus, bacteria that naturally provide some protection against HIV, with genes that will further enhance this protection. If the bacteria do not form colonies inside the patient, the person must repeatedly ingest the modified bacteria in order to get the required doses. Enabling the bacteria to form a colony could provide a more long-term solution, but could also raise safety concerns as interactions between bacteria and the human body are less well understood than with traditional drugs. There are concerns that horizontal gene transfer to other bacteria could have unknown effects.
In certain situations where strong electroosmotic flow toward the cathode is undesirable, the inner surface of the capillary can be coated with polymers, surfactants, or small molecules to reduce electroosmosis to very low levels, restoring the normal direction of migration (anions toward the anode, cations toward the cathode). CE instrumentation typically includes power supplies with reversible polarity, allowing the same instrument to be used in "normal" mode (with EOF and detection near the cathodic end of the capillary) and "reverse" mode (with EOF suppressed or reversed, and detection near the anodic end of the capillary). One of the most common approaches to suppressing EOF, reported by Stellan Hjertén in 1985, is to create a covalently attached layer of linear polyacrylamide. The silica surface of the capillary is first modified with a silane reagent bearing a polymerizable vinyl group (e.g. 3-methacryloxypropyltrimethoxysilane), followed by introduction of acrylamide monomer and a free radical initiator. The acrylamide is polymerized in situ, forming long linear chains, some of which are covalently attached to the wall-bound silane reagent. Numerous other strategies for covalent modification of capillary surfaces exist. Dynamic or adsorbed coatings (which can include polymers or small molecules) are also common. For example, in capillary sequencing of DNA, the sieving polymer (typically polydimethylacrylamide) suppresses electroosmotic flow to very low levels.
In the 19th century, in Bielefeld, Germany, epileptic patients were given the prescription to spend time each day taking care of cats and dogs. The contact with the animals was found to reduce the occurrence of seizures. As early as the 1920s, people were starting to utilize the human–animal bond not just for healing, but also granting independence through service animals. In 1929, The Seeing Eye Inc. school formed to train guide dogs for the blind in the United States, inspired by dogs being trained to guide World War I veterans in Europe. Furthermore, the idea is that the human-animal bond can provide health benefits to humans as the animals "appeal to fundamental human needs for companionship, comfort, and security..." In 1980, a team of scientists at the University of Pennsylvania found that human to animal contact was found to reduce the physiological characteristics of stress; specifically, blood pressure, heart rate, respiratory rate, anxiety, and tension were all found to correlate inversely with human–pet bonding. In some cases, despite its benefits, the human–animal bond can be used for harmful purposes. The 1990s saw an increase in social and scientific awareness of the use of companion animals as a tool for domestic violence. A 1997 study found that 80% of shelters reported women staying with them had experienced their abuser threatening or harming companion animals as a form of abuse. A 2003 study by the U.S.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.